Somatix Therapy Corp. has received an exclusive worldwidelicense to use of a gene therapy involving genetically modifiedautologous myoblasts, or muscle cells, the company saidWednesday.
The Alameda, Calif., company (NASDAQ:SOMA) gained therights through license of a patent application filed by StanfordUniversity.
Somatix said the license covers use of the modified myoblastsin therapy that involves genetic modification of the patient'scells to produce therapeutic substances. The approach haspotential application for hemophilia, central nervous systemdisorders and other diseases.
Somatix stock gained $1.25 to $15.63.
(c) 1997 American Health Consultants. All rights reserved.